Brainscape's Knowledge GenomeTM

Browse over 1 million classes created by top students, professors, publishers, and experts.


See full index

NAPLEX 2022 > TRADITIONAL CHEMOTHERAPY AGENT SPECIFICS > Flashcards

TRADITIONAL CHEMOTHERAPY AGENT SPECIFICS Flashcards

1
Q

WHICH CHEMO CLASSES ARE CELL CYCLE INDEPENDENT AGENTS

A

ALKYLATING AGENTS
PLATINUM-BASED COMPOUNDS
ANTHRACYCLINES

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
2
Q

WHICH AGENTS ARE IN THE ALKYLATING AGENTS CLASS?

A

CYCLOPHOSPHAMIDE, IFOSFAMIDE
CARMUSTINE, LOMUSTINE
BUSULFAN

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
3
Q

WHICH AGENTS ARE PLATINUM BASED COMPOUNDS?

A

CISPLATIN
CARBOPLATIN
OXALIPLATIN

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
4
Q

WHICH ARENTS ARE ANTHRACYCLINES

A

DOXORUBICIN, DAUNORUBICIN
MITOXANTRONE

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
5
Q

WHICH CHEMO CLASSES ARE CELL CYCLE SPECIFIC AGENTS

A

TOPOISOMERASE INHIBITORS (1 AND 2)
VINCA ALKALOIDS
TAXANES
PYRIMIDINE ANALOG ANTIMETABOLITES
FOLATE ANTIMETABOLITES

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
6
Q

ALKYLATING AGENT MOA

A

CROSS LINKING DNA STRANDS, INHIBITING PROTEIN SYNTHESIS AND DNA SYNTHESIS

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
7
Q

HOW DOES MESNA WORK

A

INACTIVATES TOXIC METABOLITE ACROLEIN THAT CONCENTRATES IN THE BLADDER

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
8
Q

WHAT IS THE TOXIC METABOLITE OF CYCLOPHOSPHAMIDE AND IFOSFAMIDE

A

ACROLEIN

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
9
Q

PLATINUM BASED COMPOUNDS MOA

A

CROSS LINK DNA, INHIBITING DNA SYNTHESIS AND CELL REPLICATION

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
10
Q

PLATINUM BASED COMPOUND WARNING

A

PLATINUM COMPONENT CAN CAUSE TOXICITIES RELATED TO HEAVY EMTAL POISONING, LIKE NEUROPATHY, OTOTOXICITY, AND NEPHROPATHY

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
11
Q

CARBOPLATIN CALVERT FORMULA

A

USED TO CALCULATE DOSE FOR TARGET AUC
DOSE = (TARGET AUC)X(GFR+25)
AUC CAN RANGE FROM 2-8
GFR IS CAPPED AT 125

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
12
Q

PLATINUM BASED COMPOUND BOXED WARNING

A

ANAPHYLACTIC LIKE REACTIONS
RISK INCREASES WITH REPEATED EXPOSURE

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
13
Q

WHICH ANTHRACYCLINES HAVE A UNIQUE COLOR

A

DOXORUBICIN IS RED
MITOCANTRONE IS BLUE

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
14
Q

TOPOISOMERASE 1 INHIBITOR INHIBITS WHICH PHASE

A

S PHASE

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
15
Q

TOPIOSOMERASE 2 INHIBITORS INHIBIT WHICH PHASE

A

BLOCK G2 PHASE

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
16
Q

VINCA ALKALOIDS MOA
WHICH PHASE?

A

INHIBIT FUNCTION OF MICROTUBULES IN M PHASE

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
17
Q

VINCA ALKALOIDS THAT ARE ASSOCIATED WITH MORE BONE MARROW SUPPRESSION THAN VINCRISTINE

A

VINBLASTINE AND VINOREBLINE
BOTH HAVE B IN NAME

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
18
Q

TAXANES MOA AND PHASE

A

INHIBIT FUNCTION OF MICROTUBULES IN M PHASE

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
19
Q

TAXANE BOXED WARNING

A

INFUSION RELATED HYPERSENSITIVITY REACTIONS AND FATAL ANAPHYLAXIS WITH ALL TAXANES

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
20
Q

TAXANE DRUG INTERACTION WITH ANOTHER CHEMO CLASS

A

TAXANE ELIMINATION REDUCED WHEN GIVE AFTER CISPLATIN/CARBOPLATIN
GIVE TAXANES BEFORE

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
21
Q

WHICH TAXANE DOES NOT CAUSE HYPERSENSITIVITY AND DOES NOT NEED PREMEDICATION

A

PACLITAXEL

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
22
Q

PYRIMIDINE ANALOG ANTIMETABOLITES MOA AND PHASE

A

INHIBIT PSYRIMIDINE SYNTHESIS DURING S PHASE

23
Q

WHAT METABOLITES IS INCORPORATED INTO RNA WHEN PYRIMIDINE ANALOGS ARE USED

A

F-UMP
S-dUMP

24
Q

FOLATE ANTIMETABOLITE MOA AND PHASE

A

INTERFERE WITH ENZYMES INVOLVED IN FOLIC ACID CYCLE, BLOCKING PURINE AND PYRIMIDINE SYNTHESIS DURING S PHASE

25
Q

HOW IS DOSING DIFFERENT FOR METHOTREXATE IN RA/PSORIASIS VS ONCOLOGY

A

DOSES IS MUCH HIGHER IN ONCOLOGY
RA/PSORIASIS DOSES ARE WEEKLY DOSES

26
Q

WHAT IS ADMINISTERED TO ↓ RISK OF NEPHROTOXICITY WITH METHOTREXATE

A

HYDRATION AND IV NA-BICARB TO ALKALINIZE THE URINE

27
Q

IF WANT TO USE SUPPLEMENTS TO ↓ RISK OF SIDE EFFECTS WITH FOLATE ANTIMETABOLITES, WHICH ONES ARE USED?

A

A REDUCED FORM OF FOLIC ACID IS NEEDED (REGULAR FOLATE DOES NOT WORK)

28
Q

WHICH MEDICATIONS CAN INTERACT WITH METHOTREXATE

A

NSAIDS
SALICYLATES

29
Q

WHICH mTOR AGENTS CAN BE USED IN ONCOLOGY

A

EVEROLIMUS
TEMSIROLIMUS

30
Q

EVEROLIMUS SIDE EFFECTS

A

MOUTH ULCERS/STOMATITIS
RASH
INTERSTITIAL LUNG DISEASE
PERIPHERAL EDEMA
DYSLIPIDEMIA
↑BP

31
Q

BEVACIZUMAB MOA

A

VEGF INHIBITOR

32
Q

VEGF INHIBITOR CONCERNS

A

IMPAIRS WOUND HEALING - DO NOT GIVE 28 DAYS BEFORE OR AFTER SURGERY
SEVERE/FATAL BLEEDING
GI PERFORATION

33
Q

TRASTUZUMAB MOA

A

HER2 INHIBITOR

34
Q

HER2 INHIBITOR CONCERNS

A

MONITOR LVEF DUE TO RISK OF HF

35
Q

CETUXIMAB MOA

A

EGFR INHIBITOR

36
Q

EGFR INHIBITOR PHARMACOGENOMICS

A

FOR LUNG CANCER
MUST BE KRAS WILD TYPE TO USE
MUTATION PREDICTS POOR RESPONSE

37
Q

EGFR INHIBITOR CONCERNS

A

ACNEIFORM RASH
RASH INDICATES BETTER RESPONSE TO DRUG
AVOID SUNLIGHT
USE EMOLLIENTS, STEROIDS, ABX TO REDUCE SKIN DAMAGE

38
Q

RITUXIMAB MOA

A

LEUKOCYTE CLUSTER OF DIFFERENTIATION (CD) ANTIGEN INHIBITOR

39
Q

CD-INHIBITOR CONCERNS

A

PREMEDICATE WITH BENADRYLL, APAP, STEROID DUE TO RISK OF INFUSION REACTIONS

40
Q

PROGRAMMED DEATH RECEPTOR-1 (PD-1) INHIBITOR CONCERNS

A

IMMUNE-MEDIATED TOXICITIES

41
Q

CYTOTOXIC T-LYMPHOCYTE ANTIGEN-4 (CTLA-4) INHIBITOR CONCERN

A

REMS PROGRAM
FATAL IMMUNE MEDIATED REACTION

42
Q

WHAT TESTING SHOULD BE DONE BEFORE ADMINISTERING TKIs

A

PHARMACOGENOMIC TESTING TO IDENTIFY PATIENTS WHO WILL BENEFIT

43
Q

IMATINIB USE AND MOA

A

CHRONIC MYELOGENOUS LEUKEMIA (CML)
BCR-ABL INHIBITOR

44
Q

IMATINIB CONCERNS

A

MUST BE BCR-ABL POSITIVE TO USE
CAN CAUSE FLUID RETENTION AND EDEMA

45
Q

BRAF INHIBITOR USE

A

USED IN MELANOMA

46
Q

BRAF INHIBITOR CONCERNS

A

MUST BE BRAF V600E OR V600K MUTATION POSITIVE
NEW MALIGNANCIES CAN OCCUR

47
Q

MITOGEN-ACTIVATED EXTRACELLULAR KINASE (MEK) 1 AND 2 INHIBITOR CONCERNS

A

USED IN COMBINATION WITH BRAF INHIBITORS IN PATIENTS WITH BRAF V600E AND V600K MUTATIONS

48
Q

EGFR INHIBITOR USE

A

NON-SMALL CELL LUNG CANCER (NSCLC)

49
Q

EGFR INHIBITOR CONCERNS

A

MUST BE EGFR MUTATION POSITIVE
RASH THAT INDICATES A BETTER RESPONSE

50
Q

ANAPLASTIC LYMPHOMA KINASE (ALK) INHIBITORS USE

A

NON-SMALL CELL LUNG CANCER (NSCLC)

51
Q

ANAPLASTIC LYMPHOMA KINASE (ALK) INHIBITORS CONCERNS

A

MUST BE ALK MUTATION POSITIVE

52
Q

COMMON TOXICITIES WITH TKIs

A

THYROID GLAND (HYPOTHYROIDISM)
HEART (QT PRLONGATION)
SKIN (RASH)
BLOOD VESSELS (HTN, HAND AND FOOT SYNDROME)
LIVER (HEPATOTOXICITY)
INTESTINES (DIARRHEA)

53
Q

WHICH ORAL CHEMO AGENTS SHOULD BE GIVEN WITH FOOD

A

IMATINIB
CAPECITABINE

54
Q

WHICH ORAL CHEMO AGENTS CAN BE TAKEN WITHOUT REGARD TO FOOD

A

ANASTRAZOLE
TAMOXIFEN

NAPLEX 2022 (37 decks)

Brainscape helps you reach your goals faster, through stronger study habits.
© 2024 Bold Learning Solutions. Terms and Conditions